Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on generative design for therapeutics, has scheduled its Q2 2025 earnings report and business update for August 12, 2025, after market close.
The company will host a conference call at 4:30 PM ET to discuss business developments, financial results, and future outlook. Investors can access the live webcast through Absci's investor relations website, with a replay available after the event.
Absci Corporation (Nasdaq: ABSI), un'azienda biofarmaceutica in fase clinica specializzata nel design generativo per terapie, ha programmato il resoconto dei risultati del secondo trimestre 2025 e l'aggiornamento aziendale per il 12 agosto 2025, dopo la chiusura del mercato.
L'azienda terrà una conference call alle 16:30 ET per discutere degli sviluppi aziendali, dei risultati finanziari e delle prospettive future. Gli investitori potranno seguire la diretta streaming tramite il sito web delle relazioni con gli investitori di Absci, con una replica disponibile dopo l'evento.
Absci Corporation (Nasdaq: ABSI), una empresa biofarmacéutica en etapa clínica enfocada en el diseño generativo para terapias, ha programado su informe de resultados del segundo trimestre de 2025 y actualización empresarial para el 12 de agosto de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia a las 4:30 PM ET para discutir desarrollos comerciales, resultados financieros y perspectivas futuras. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de Absci, con una repetición disponible después del evento.
Absci Corporation (나스닥: ABSI)는 치료제용 생성적 설계에 중점을 둔 임상 단계의 생명공학 회사로, 2025년 8월 12일 2분기 실적 보고서 및 사업 업데이트를 시장 마감 후에 발표할 예정입니다.
회사는 오후 4:30 ET에 컨퍼런스 콜을 개최하여 사업 진행 상황, 재무 결과 및 향후 전망에 대해 논의할 예정입니다. 투자자들은 Absci의 투자자 관계 웹사이트를 통해 생중계에 접속할 수 있으며, 행사 후 다시보기도 제공됩니다.
Absci Corporation (Nasdaq : ABSI), une société biopharmaceutique en phase clinique axée sur la conception générative pour les thérapeutiques, a programmé son rapport sur les résultats du deuxième trimestre 2025 et une mise à jour commerciale pour le 12 août 2025, après la clôture du marché.
La société organisera une conférence téléphonique à 16h30 ET pour discuter des développements commerciaux, des résultats financiers et des perspectives futures. Les investisseurs pourront accéder à la diffusion en direct via le site des relations investisseurs d'Absci, avec un replay disponible après l'événement.
Absci Corporation (Nasdaq: ABSI), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Fokus auf generatives Design für Therapeutika, hat seinen Ergebnisbericht für das zweite Quartal 2025 und ein Unternehmensupdate für den 12. August 2025 nach Börsenschluss angekündigt.
Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um Geschäftsentwicklungen, Finanzergebnisse und zukünftige Aussichten zu besprechen. Investoren können den Live-Webcast über die Investor-Relations-Website von Absci verfolgen, eine Wiederholung steht nach der Veranstaltung zur Verfügung.
- None.
- None.
VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025.
Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.
Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
When will Absci (NASDAQ:ABSI) report Q2 2025 earnings?
What time is Absci's Q2 2025 earnings conference call?
How can investors access Absci's Q2 2025 earnings call?
What will Absci discuss in their Q2 2025 earnings call?
